Atmosphere-ph.ru

Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru

ИНТЕРНЕТ-МАГАЗИН

Телефон издательства

Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 3

Антибактериальная терапия при стабильной бронхоэктазии у взрослых
Э.Х. Анаев

References

1. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. European Respiratory Society guidelines for the management of adult bronchiectasis. The European Respiratory Journal 2017 Sep;50(3). pii: 1700629.
2. Magis-Escurra C, Reijers MH. Bronchiectasis. BMJ Clinical Evidence 2015 Feb;2015. pii: 1507.
3. Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, Smeeth L, Brown JS. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. The European Respiratory Journal 2016 Jan;47(1):186-93.
4. Fjaellegaard K, Sin MD, Browatzki A, Ulrik CS. Antibiotic therapy for stable non-CF bronchiectasis in adults – a systematic review. Chronic Respiratory Disease 2017 May;14(2):174-86.
5. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010 Jul;65(Suppl 1):i1-58.
6. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Annals of the American Thoracic Society 2014 Mar;11(3):425-34.
7. Falagas ME, Trigkidis KK, Vardakas KZ. Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: a systematic review. International Journal of Antimicrobial Agents 2015 Mar;45(3):221-33.
8. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clinical Microbiology and Infection 2010 Aug;16(8):1230-6.
9. Chorepsima S, Kechagias KS, Kalimeris G, Triarides NA, Falagas ME. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis. Drug Design, Development and Therapy 2018 Nov;12:4059-66.
10. Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. The Lancet. Respiratory Medicine 2018 Sep;6(9):715-26.
11. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respiratory Medicine 1999 Jul;93(7):476-80.
12. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O’Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2000 Aug;162(2 Pt 1):481-5.
13. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Annals of Pharmacotherapy 2005 Jan;39(1):39-44.
14. Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001 Sep;120(3 Suppl):114S-7S.
15. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1997 Jun;155(6):2024-9.
16. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2011 Feb;183(4):491-9.
17. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012 Oct;186(7):657-65.
18. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004 Jun;59(6):540-1.
19. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, Amsden GW. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine 2005;4(2):117-22.
20. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respiratory Medicine 2008 Oct;102(10):1494-6.
21. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. The Lancet 2012 Aug;380(9842):660-7.
22. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013 Mar;309(12):1251-9.
23. Diego AD, Milara J, Martinez-Moragon E, Palop M, León M, Cortijo J. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology 2013 Oct;18(7):1056-62.
24. Coeman M, van Durme Y, Bauters F, Deschepper E, Demedts I, Smeets P, Joos G, Brusselle G. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Therapeutic Advances in Respiratory Disease 2011 Dec;5(6):377-86.
25. Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, Ooi GC, Amitani R, Tanaka E. A pilot study of low-dose erythromycin in bronchiectasis. The European Respiratory Journal 1999 Feb;13(2):361-4.
26. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respiratory Medicine 2011 Jun;105(6):946-9.
27. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013 Mar;309(12):1260-7.
28. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987 Feb;106(2):196-204.
29. Rayner CF, Tillotson G, Cole PJ, Wilson R. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. Journal of Antimicrobial Chemotherapy 1994 Jul;34(1):149-56.
30. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013 Sep;68(9):812-7.
31. Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. The European Respiratory Journal 1997 Aug;10(8):1754-60.
32. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respiratory Medicine 2007 Aug;101(8):1633-8.
33. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132(5):1565-72.
34. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O’Donnell A, Alder J, Reimnitz P, Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. The European Respiratory Journal 2013 May;41(5):1107-15.
35. Antoniu S, Azoicai D. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion in Investigational Drugs 2013 May;22(5):671-3.
36. Dhar R, Anwar GA, Bourke SC, Doherty L, Middleton P, Ward C, Rutherford RM. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010 Jun;65(6):553.
37. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine 2014 Apr;189(8):975-82.
38. Barker AF, O’Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O’Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. The Lancet. Respiratory Medicine 2014 Sep;2(9):738-49.
39. Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Archivos de Bronconeumologia 2018 Feb;54:79-87.
40. Suarez‐Cuartin G, Chalmers JD, Sibila O. Diagnostic challenges of bronchiectasis. Respiratory Medicine 2016 Jul;116:70-7.
41. Vallieres E, Tumelty K, Tunney MM, Hannah R, Hewitt O, Elborn JS, Downey DG. Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis. The European Respiratory Journal 2017;49(4):pii:1600851.
42. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non‐cystic fibrosis bronchiectasis. Respiratory Medicine 2012 Mar;106:356-60.
43. Bell SC, Elborn JS, Byrnes CA. Bronchiectasis: treatment decisions for pulmonary exacerbations and their prevention. Respirology 2018 Nov;23(11):1006-22.

References
1. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. European Respiratory Society guidelines for the management of adult bronchiectasis. The European Respiratory Journal 2017 Sep;50(3). pii: 1700629.
2. Magis-Escurra C, Reijers MH. Bronchiectasis. BMJ Clinical Evidence 2015 Feb;2015. pii: 1507.
3. Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, Smeeth L, Brown JS. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. The European Respiratory Journal 2016 Jan;47(1):186-93.
4. Fjaellegaard K, Sin MD, Browatzki A, Ulrik CS. Antibiotic therapy for stable non-CF bronchiectasis in adults – a systematic review. Chronic Respiratory Disease 2017 May;14(2):174-86.
5. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010 Jul;65(Suppl 1):i1-58.
6. Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Annals of the American Thoracic Society 2014 Mar;11(3):425-34.
7. Falagas ME, Trigkidis KK, Vardakas KZ. Inhaled antibiotics beyond aminoglycosides, polymyxins and aztreonam: a systematic review. International Journal of Antimicrobial Agents 2015 Mar;45(3):221-33.
8. Korbila IP, Michalopoulos A, Rafailidis PI, Nikita D, Samonis G, Falagas ME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clinical Microbiology and Infection 2010 Aug;16(8):1230-6.
9. Chorepsima S, Kechagias KS, Kalimeris G, Triarides NA, Falagas ME. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis. Drug Design, Development and Therapy 2018 Nov;12:4059-66.
10. Chalmers JD, Chotirmall SH. Bronchiectasis: new therapies and new perspectives. The Lancet. Respiratory Medicine 2018 Sep;6(9):715-26.
11. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respiratory Medicine 1999 Jul;93(7):476-80.
12. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O’Donnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2000 Aug;162(2 Pt 1):481-5.
13. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Annals of Pharmacotherapy 2005 Jan;39(1):39-44.
14. Couch LA. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001 Sep;120(3 Suppl):114S-7S.
15. Lin HC, Cheng HF, Wang CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1997 Jun;155(6):2024-9.
16. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2011 Feb;183(4):491-9.
17. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. American Journal of Respiratory and Critical Care Medicine 2012 Oct;186(7):657-65.
18. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004 Jun;59(6):540-1.
19. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, Amsden GW. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treatments in Respiratory Medicine 2005;4(2):117-22.
20. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respiratory Medicine 2008 Oct;102(10):1494-6.
21. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. The Lancet 2012 Aug;380(9842):660-7.
22. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013 Mar;309(12):1251-9.
23. Diego AD, Milara J, Martinez-Moragon E, Palop M, León M, Cortijo J. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology 2013 Oct;18(7):1056-62.
24. Coeman M, van Durme Y, Bauters F, Deschepper E, Demedts I, Smeets P, Joos G, Brusselle G. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: a retrospective observational study. Therapeutic Advances in Respiratory Disease 2011 Dec;5(6):377-86.
25. Tsang KW, Ho PI, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, Ooi GC, Amitani R, Tanaka E. A pilot study of low-dose erythromycin in bronchiectasis. The European Respiratory Journal 1999 Feb;13(2):361-4.
26. Serisier DJ, Martin ML. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respiratory Medicine 2011 Jun;105(6):946-9.
27. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, Biga S, Schlebusch S, Dash P, Bowler SD. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013 Mar;309(12):1260-7.
28. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987 Feb;106(2):196-204.
29. Rayner CF, Tillotson G, Cole PJ, Wilson R. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. Journal of Antimicrobial Chemotherapy 1994 Jul;34(1):149-56.
30. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013 Sep;68(9):812-7.
31. Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. The European Respiratory Journal 1997 Aug;10(8):1754-60.
32. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respiratory Medicine 2007 Aug;101(8):1633-8.
33. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132(5):1565-72.
34. Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O’Donnell A, Alder J, Reimnitz P, Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. The European Respiratory Journal 2013 May;41(5):1107-15.
35. Antoniu S, Azoicai D. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion in Investigational Drugs 2013 May;22(5):671-3.
36. Dhar R, Anwar GA, Bourke SC, Doherty L, Middleton P, Ward C, Rutherford RM. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010 Jun;65(6):553.
37. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine 2014 Apr;189(8):975-82.
38. Barker AF, O’Donnell AE, Flume P, Thompson PJ, Ruzi JD, de Gracia J, Boersma WG, De Soyza A, Shao L, Zhang J, Haas L, Lewis SA, Leitzinger S, Montgomery AB, McKevitt MT, Gossage D, Quittner AL, O’Riordan TG. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. The Lancet. Respiratory Medicine 2014 Sep;2(9):738-49.
39. Martínez-García MÁ, Máiz L, Olveira C, Girón RM, de la Rosa D, Blanco M, Cantón R, Vendrell M, Polverino E, de Gracia J, Prados C. Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults. Archivos de Bronconeumologia 2018 Feb;54:79-87.
40. Suarez‐Cuartin G, Chalmers JD, Sibila O. Diagnostic challenges of bronchiectasis. Respiratory Medicine 2016 Jul;116:70-7.
41. Vallieres E, Tumelty K, Tunney MM, Hannah R, Hewitt O, Elborn JS, Downey DG. Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis. The European Respiratory Journal 2017;49(4):pii:1600851.
42. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non‐cystic fibrosis bronchiectasis. Respiratory Medicine 2012 Mar;106:356-60.
43. Bell SC, Elborn JS, Byrnes CA. Bronchiectasis: treatment decisions for pulmonary exacerbations and their prevention. Respirology 2018 Nov;23(11):1006-22.

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]